[Appropriate use of anti-MRSA drugs (discussion)].
Sunakawa
Keisuke
K
D000081:Acetamides; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D017714:Community-Acquired Infections / Q000382:microbiology; D003428:Cross Infection / Q000382:microbiology; D003982:Dibekacin / Q000031:analogs & derivatives; D006801:Humans; D016867:Immunocompromised Host; D000069349:Linezolid; D016106:Methicillin Resistance; D023303:Oxazolidinones; D017410:Practice Guidelines as Topic; D013211:Staphylococcus aureus; D017334:Teicoplanin; D014640:Vancomycin
D000081:Acetamides; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D003982:Dibekacin; D017334:Teicoplanin; D014640:Vancomycin; C031986:arbekacin; D000069349:Linezolid